{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016752","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.799927+00:00","generated_at":"2026-06-22T03:22:20.218885+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Kala Pharma reports $52.4M cash; plans Phase 2/3 trial for KPI-012 in Q4 2022 with data 1Q 2024","bullets":["Cash and equivalents of $52.4M as of Sept 30, 2022, expected to fund operations into Q2 2024.","Plans to initiate Phase 2/3 trial of KPI-012 for PCED in Q4 2022; topline data expected Q1 2024.","Appointed Marjan Farid, M.D., to Board of Directors in November 2022.","Effected 1-for-50 reverse stock split on October 20, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016752","json":"https://secwatch.observer/filing/0001558370-22-016752.json","markdown":"https://secwatch.observer/filing/0001558370-22-016752.md","text":"https://secwatch.observer/filing/0001558370-22-016752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837022016752/0001558370-22-016752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837022016752/kala-20221108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:22:20.218885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d73a561c2ece0944c910b284548a3daa5c41a486","claim":"KALA BIO, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837022016752/0001558370-22-016752-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}